⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu Hu-Yun-Long Zhang Yi-Fan Zhou Yi-Yu Chen Tong Fu Ming-Liang Jin Ya-Xin Zhao Yi-Fan Xie Xiaohua Zeng Xi Jin Yi‐Zhou Jiang Zhi‐Ming Shao

View at Publisher

Ask AI

Bookmark

Share

Key Points

Secondary resistance to endocrine therapy was observed in the SNF3 subtype of breast cancer, signaling a need for tailored approaches.
The study highlights precision treatment implications for HR+/HER2- breast cancer patients, suggesting a shift from one-size-fits-all strategies.
Assessment of treatment response demonstrated notable differences among subtypes, indicating varying therapeutic needs and potential outcomes.
This exploration into subtype-directed precision treatment calls for further research to optimize therapeutic interventions in breast cancer care.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals secondary resistance to endocrine therapy in the SNF3 subtype, highlighting precision treatment efficacy.

Abstract

Fig. S2 Secondary resistance to endocrine therapy of the SNF3 subtype.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcab2 https://doi.org/10.1158/0008-5472.30363484

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
2Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
3Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
4Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
5Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025

Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025